287 related articles for article (PubMed ID: 23636669)
1. Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists.
Pecci A
Int J Hematol; 2013 Jul; 98(1):34-47. PubMed ID: 23636669
[TBL] [Abstract][Full Text] [Related]
2. Guest editorial: Pathophysiology and management of thrombocytopenia: possible clinical application of TPO receptor agonists.
Tomiyama Y
Int J Hematol; 2013 Jul; 98(1):8-9. PubMed ID: 23793996
[No Abstract] [Full Text] [Related]
3. The biology of thrombopoietin and thrombopoietin receptor agonists.
Kuter DJ
Int J Hematol; 2013 Jul; 98(1):10-23. PubMed ID: 23821332
[TBL] [Abstract][Full Text] [Related]
4. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
Elife; 2021 Jun; 10():. PubMed ID: 34059198
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiology and management of primary immune thrombocytopenia.
Kashiwagi H; Tomiyama Y
Int J Hematol; 2013 Jul; 98(1):24-33. PubMed ID: 23702914
[TBL] [Abstract][Full Text] [Related]
6. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.
Townsley DM; Desmond R; Dunbar CE; Young NS
Int J Hematol; 2013 Jul; 98(1):48-55. PubMed ID: 23690288
[TBL] [Abstract][Full Text] [Related]
7. Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia.
Bastida JM; Gonzalez-Porras JR; Rivera J; Lozano ML
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919295
[TBL] [Abstract][Full Text] [Related]
8. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.
Machlus KR; Wu SK; Vijey P; Soussou TS; Liu ZJ; Shacham E; Unger TJ; Kashyap T; Klebanov B; Sola-Visner M; Crochiere M; Italiano JE; Landesman Y
Blood; 2017 Aug; 130(9):1132-1143. PubMed ID: 28630120
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists.
Bussel J; Kulasekararaj A; Cooper N; Verma A; Steidl U; Semple JW; Will B
Semin Hematol; 2019 Oct; 56(4):262-278. PubMed ID: 31836033
[TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin in thrombocytopenias of childhood.
Dame C
Semin Thromb Hemost; 2001 Jun; 27(3):215-28. PubMed ID: 11446655
[TBL] [Abstract][Full Text] [Related]
11. Milestones in understanding platelet production: a historical overview.
Kuter DJ
Br J Haematol; 2014 Apr; 165(2):248-58. PubMed ID: 24528208
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin receptor agonists in primary immune thrombocytopenia.
Siegal D; Crowther M; Cuker A
Semin Hematol; 2013 Jan; 50 Suppl 1(0 1):S18-21. PubMed ID: 23664510
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
Makar RS; Zhukov OS; Sahud MA; Kuter DJ
Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253
[TBL] [Abstract][Full Text] [Related]
14. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
[TBL] [Abstract][Full Text] [Related]
15. F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents.
Fox NE; Lim J; Chen R; Geddis AE
Exp Hematol; 2010 May; 38(5):384-91. PubMed ID: 20188141
[TBL] [Abstract][Full Text] [Related]
16. Thrombopoietic agents.
Stasi R; Bosworth J; Rhodes E; Shannon MS; Willis F; Gordon-Smith EC
Blood Rev; 2010; 24(4-5):179-90. PubMed ID: 20493600
[TBL] [Abstract][Full Text] [Related]
17. AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis.
Fukushima-Shintani M; Suzuki K; Iwatsuki Y; Abe M; Sugasawa K; Hirayama F; Kawasaki T
Exp Hematol; 2008 Oct; 36(10):1337-42. PubMed ID: 18619724
[TBL] [Abstract][Full Text] [Related]
18. The contribution of mouse models to the understanding of constitutional thrombocytopenia.
Léon C; Dupuis A; Gachet C; Lanza F
Haematologica; 2016 Aug; 101(8):896-908. PubMed ID: 27478199
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in liver diseases: Meta-analysis of RCTs.
Qi X; De Stefano V; Guo X; Fan D
Thromb Haemost; 2015 Jun; 113(6):1378-80. PubMed ID: 25761530
[No Abstract] [Full Text] [Related]
20. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
